|
| Takeda receives FDA complete response letter regarding NDA for fixed-dose combination of alogliptin and ACTOS |
4 Sep 09, 09:10 |
|
| Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl). |
| more |
|
